XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Investments (Tables)
 9 Months Ended
Sep. 30, 2022
Long Term Investment Abstract  
Schedule of ownership percentages of investee
   Ownership percentage    
   September 30,   December 31,   Accounting
Name of related party  2022   2021   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.70%   0.70%  Cost Method
BioHopeKing Corporation   5.90%   5.90%  Cost Method
BioFirst Corporation   15.99%   15.99%  Equity Method
Rgene Corporation   31.62%   31.62%  Equity Method

 
Schedule of extent the investee relies
Name of related party   The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Collaborating with the Company to develop and commercialize drugs
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs

  
Schedule of long-term investment
   September 30,
2022		   December 31,
2021		 
   (Unaudited)     
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $6,948   $7,941 
Genepharm Biotech Corporation   21,213    24,244 
BioHopeKing Corporation   787,999    900,570 
Sub total   816,160    932,755 
Equity Method Investments, net          
BioFirst Corporation   
-
    
-
 
Rgene Corporation   
-
    
-
 
Total  $816,160   $932,755 

 
Schedule of balance sheet
   September 30,
2022		   December 31,
2021		 
   (Unaudited)     
Current Assets  $1,680,108   $2,205,669 
Non-current Assets   740,874    959,454 
Current Liabilities   2,512,708    2,909,703 
Non-current Liabilities   100,261    32,522 
Stockholders’ Equity (Deficit)   (191,987)   222,898 

 

   September 30,
2022		   December 31,
2021		 
   (Unaudited)     
Current Assets  $497,633   $73,452 
Noncurrent Assets   311,612    374,423 
Current Liabilities   1,796,491    1,934,786 
Noncurrent Liabilities   20,340    
-
 
Shareholders’ Deficit   (1,007,586)   (1,486,911)

 
Schedule of statements of operation
   Nine Months Ended
September 30,		 
   2022   2021 
   (Unaudited)     
Net sales  $23,079   $17,451 
Gross profit   5,747    5,414 
Net loss   (993,643)   (887,230)
Share of losses from investments accounted for using the equity method   
-
    (193,147)

 

   Nine Months Ended
September 30,		 
   2022   2021 
   (Unaudited) 
Net sales  $
-
   $
-
 
Gross Profit   
-
    
-
 
Net loss   (450,995)   (411,897)
Share of loss from investments accounted for using the equity method   
-
    
-
 

 
Schedule of equity investments
   Nine Months Ended
September 30,		 
   2022   2021 
   (Unaudited) 
Share of equity method investee losses  $
         -
   $(193,147)